Advanced Lymphoma

Oncology·MeSH: Lymphoma

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

120 drugs in development·5 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(10)

Drug	Company
Adavosertib	ENANTA PHARMACEUTICALS INC (ENTA)
Afatinib	Relay Therapeutics, Inc. (RLAY)
Afatinib Dimaleate	Relay Therapeutics, Inc. (RLAY)
Capivasertib	ENANTA PHARMACEUTICALS INC (ENTA)
EGFR-TKI inhibitor based on investigator's choice	ADMA BIOLOGICS, INC. (ADMA)
Larotrectinib	ENANTA PHARMACEUTICALS INC (ENTA)
Larotrectinib Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)
Osimertinib	Relay Therapeutics, Inc. (RLAY)
Sapanisertib	Relay Therapeutics, Inc. (RLAY)
Taselisib	Relay Therapeutics, Inc. (RLAY)

Phase 2(108)

Drug	Company
Adavosertib	CURIS INC (CRIS)
Adavosertib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Adavosertib	ADMA BIOLOGICS, INC. (ADMA)
Adavosertib	Relay Therapeutics, Inc. (RLAY)
Afatinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Afatinib	CURIS INC (CRIS)
Afatinib	ENANTA PHARMACEUTICALS INC (ENTA)
Afatinib	ADMA BIOLOGICS, INC. (ADMA)
Afatinib Dimaleate	CURIS INC (CRIS)
Afatinib Dimaleate	BIOCRYST PHARMACEUTICALS INC (BCRX)
Afatinib Dimaleate	ADMA BIOLOGICS, INC. (ADMA)
Afatinib Dimaleate	ENANTA PHARMACEUTICALS INC (ENTA)
Binimetinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Binimetinib	CURIS INC (CRIS)
Binimetinib	ADMA BIOLOGICS, INC. (ADMA)
Binimetinib	ENANTA PHARMACEUTICALS INC (ENTA)
Capivasertib	ADMA BIOLOGICS, INC. (ADMA)
Capivasertib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Capivasertib	CURIS INC (CRIS)
Copanlisib	ADMA BIOLOGICS, INC. (ADMA)
Copanlisib	Relay Therapeutics, Inc. (RLAY)
Copanlisib	CURIS INC (CRIS)
Copanlisib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Copanlisib Hydrochloride	CURIS INC (CRIS)
Copanlisib Hydrochloride	ADMA BIOLOGICS, INC. (ADMA)
Copanlisib Hydrochloride	BIOCRYST PHARMACEUTICALS INC (BCRX)
Crizotinib	Relay Therapeutics, Inc. (RLAY)
Crizotinib	ADMA BIOLOGICS, INC. (ADMA)
Crizotinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Crizotinib	CURIS INC (CRIS)
Dabrafenib	ADMA BIOLOGICS, INC. (ADMA)
Dabrafenib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Dabrafenib	Relay Therapeutics, Inc. (RLAY)
Dabrafenib	CURIS INC (CRIS)
Dabrafenib Mesylate	Relay Therapeutics, Inc. (RLAY)
Dabrafenib Mesylate	ADMA BIOLOGICS, INC. (ADMA)
Dabrafenib Mesylate	BIOCRYST PHARMACEUTICALS INC (BCRX)
Dabrafenib Mesylate	CURIS INC (CRIS)
Dasatinib	ADMA BIOLOGICS, INC. (ADMA)
Dasatinib	CURIS INC (CRIS)
Dasatinib	Relay Therapeutics, Inc. (RLAY)
Dasatinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Defactinib	CURIS INC (CRIS)
Defactinib	ADMA BIOLOGICS, INC. (ADMA)
Defactinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Defactinib	Relay Therapeutics, Inc. (RLAY)
Defactinib Hydrochloride	ADMA BIOLOGICS, INC. (ADMA)
Defactinib Hydrochloride	BIOCRYST PHARMACEUTICALS INC (BCRX)
Defactinib Hydrochloride	CURIS INC (CRIS)
Erdafitinib	ADMA BIOLOGICS, INC. (ADMA)
Erdafitinib	CURIS INC (CRIS)
Erdafitinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Erdafitinib	Relay Therapeutics, Inc. (RLAY)
Erdafitinib	ENANTA PHARMACEUTICALS INC (ENTA)
Fexagratinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Fexagratinib	Relay Therapeutics, Inc. (RLAY)
Fexagratinib	ADMA BIOLOGICS, INC. (ADMA)
Fexagratinib	CURIS INC (CRIS)
Fexagratinib	ENANTA PHARMACEUTICALS INC (ENTA)
Ipatasertib	ADMA BIOLOGICS, INC. (ADMA)
Ipatasertib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Ipatasertib	CURIS INC (CRIS)
Larotrectinib	CURIS INC (CRIS)
Larotrectinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Larotrectinib	ADMA BIOLOGICS, INC. (ADMA)
Larotrectinib	Relay Therapeutics, Inc. (RLAY)
Larotrectinib Sulfate	ADMA BIOLOGICS, INC. (ADMA)
Larotrectinib Sulfate	BIOCRYST PHARMACEUTICALS INC (BCRX)
Larotrectinib Sulfate	CURIS INC (CRIS)
Nilotinib Hydrochloride Monohydrate	ADMA BIOLOGICS, INC. (ADMA)
Osimertinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Osimertinib	ADMA BIOLOGICS, INC. (ADMA)
Osimertinib	CURIS INC (CRIS)
Pertuzumab	CURIS INC (CRIS)
Pertuzumab	Relay Therapeutics, Inc. (RLAY)
Pertuzumab	BIOCRYST PHARMACEUTICALS INC (BCRX)
Pertuzumab	ADMA BIOLOGICS, INC. (ADMA)
PI3K-beta Inhibitor GSK2636771	ADMA BIOLOGICS, INC. (ADMA)
PI3K-beta Inhibitor GSK2636771	BIOCRYST PHARMACEUTICALS INC (BCRX)
PI3K-beta Inhibitor GSK2636771	CURIS INC (CRIS)
Relatlimab	CURIS INC (CRIS)
Relatlimab	BIOCRYST PHARMACEUTICALS INC (BCRX)
Relatlimab	ADMA BIOLOGICS, INC. (ADMA)
Relatlimab	Relay Therapeutics, Inc. (RLAY)
Sapanisertib	ENANTA PHARMACEUTICALS INC (ENTA)
Sapanisertib	CURIS INC (CRIS)
Sapanisertib	ADMA BIOLOGICS, INC. (ADMA)
Sapanisertib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Selumetinib Sulfate	ADMA BIOLOGICS, INC. (ADMA)
Taselisib	ADMA BIOLOGICS, INC. (ADMA)
Taselisib	CURIS INC (CRIS)
Taselisib	ENANTA PHARMACEUTICALS INC (ENTA)
Taselisib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Trametinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Trametinib	CURIS INC (CRIS)
Trametinib	ADMA BIOLOGICS, INC. (ADMA)
Trametinib	Relay Therapeutics, Inc. (RLAY)
Ulixertinib	ADMA BIOLOGICS, INC. (ADMA)
Ulixertinib	ENANTA PHARMACEUTICALS INC (ENTA)
Ulixertinib	CURIS INC (CRIS)
Ulixertinib	Relay Therapeutics, Inc. (RLAY)
Ulixertinib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Vinblastine Sulfate	ADMA BIOLOGICS, INC. (ADMA)
Vismodegib	BIOCRYST PHARMACEUTICALS INC (BCRX)
Vismodegib	ENANTA PHARMACEUTICALS INC (ENTA)
Vismodegib	ADMA BIOLOGICS, INC. (ADMA)
Vismodegib	Relay Therapeutics, Inc. (RLAY)
Vismodegib	CURIS INC (CRIS)

Phase 1(2)

Drug	Company
BET Bromodomain Inhibitor ZEN-3694	ADMA BIOLOGICS, INC. (ADMA)
Crizotinib	ENANTA PHARMACEUTICALS INC (ENTA)

Compare drugs

Adavosertib vs Afatinib Adavosertib vs Afatinib Dimaleate Adavosertib vs Capivasertib

Frequently asked questions

How many drugs are in development for Advanced Lymphoma?

BioSniper tracks 120 drugs in development for Advanced Lymphoma across 5 companies.

How many clinical trials target Advanced Lymphoma?

There are 2 clinical trials targeting Advanced Lymphoma tracked by BioSniper.

What is the prevalence of Advanced Lymphoma?

The estimated prevalence of Advanced Lymphoma is approximately 56.0 per 100,000 population.

Deep-dive into Advanced Lymphoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis